Article Per Year (5 Year)
p-Index From 2021 - 2026
0
P-Index
This Author published in this journals
All Journal Journal of Applied Pharmaceutical Research
Manoj Kumar Sarangi, Manoj Kumar
Unknown Affiliation
Medicine & Pharmacology

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
An Overview of Tuberculosis Chemotherapy - A Literature Review Sarangi, Manoj Kumar; Padhi, Sasmita
Journal of Applied Pharmaceutical Research Vol 4 No 1 (2016)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Tuberculosis (TB) is a major global health threat. The emergence of human immunodeficiency virus (HIV) and also multi drug resistant (MDR) and extremely drug resistant (XDR)-TB poses a vital challenge to the control of the disease. For the last 50 years, no new anti-TB drug has been discovered. This literature review provides a brief discussion of existing drugs and emerging drug targets, and also of the advantages of incorporating modern drug delivery systems and immune modulators in order to improve the existing treatment regimen in terms of better efficacy, reduced drug administration frequency, shortened period of treatment and reduced drug related toxicity. The investigation for a new drug target is essential to continue the battle against MDR and XDR-TB. However, owing to the enormous cost and time involved in new drug development, improvement of the existing treatment regimen is seen to be a valid alternative. Â 
An overview of tuberculosis chemotherapy – a literature review Sarangi, Manoj Kumar; padhi, Sasmit
Journal of Applied Pharmaceutical Research Vol. 4 No. 1 (2016)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (366.268 KB)

Abstract

Tuberculosis (TB) is a major global health threat. The emergence of human immunodeficiency virus (HIV) and also multi drug resistant (MDR) and extremely drug resistant (XDR)-TB poses a vital challenge to the control of the disease. For the last 50 years, no new anti-TB drug has been discovered. This literature review provides a brief discussion of existing drugs and emerging drug targets, and also of the advantages of incorporating modern drug delivery systems and immune modulators in order to improve the existing treatment regimen in terms of better efficacy, reduced drug administration frequency, shortened period of treatment and reduced drug related toxicity. The investigation for a new drug target is essential to continue the battle against MDR and XDR-TB. However, owing to the enormous cost and time involved in new drug development, improvement of the existing treatment regimen is seen to be a valid alternative.
Co-Authors padhi, Sasmit Sasmita Padhi, Sasmita